Company: KROS
Filing Date: 2025-05-27
Form Type: DEFA14A
Source: 0001104659-25-052890
Chunk: 5

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-27
Form: DEFA14A
Chunk 5
---
, clinical trials
and preclinical studies.

These and other risks are described more fully in Keros’ filings
with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of the Company’s
Quarterly Report on Form 10-Q, filed with the SEC on May 6, 2025, and its other documents subsequently filed with or furnished
to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to
the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that
exist after the date on which they were made.

Important Additional Information and Where to Find It

On April 23, 2025, the Company filed a definitive proxy statement
on Schedule 14A (the "Proxy Statement") and form of accompanying proxy card with the SEC in connection with its 2025 Annual
Meeting and its solicitation of proxies for the Company’s director nominees and for other matters to be voted on. The Company may
also file other relevant documents with the SEC regarding its solicitation of proxies for the 2025 Annual Meeting. This communication
is not a substitute for any proxy statement or other document that the Company has filed or may file with the SEC in connection with any
solicitation by the Company. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS
FILED WITH, OR FURNISHED TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain a
copy of the Proxy Statement and any amendments or supplements to the Proxy Statement and any other relevant documents filed by the Company
with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s
website at https://ir.kerostx.com/financials-filings/sec-filings.

Certain Information Regarding Participants

This communication is neither a solicitation of a proxy or consent
nor a substitute for any proxy statement or other filings that may be made with the SEC. The Company, its directors, its director nominees
and certain of its executive officers and employees may be deemed to be participants in the solicitation of proxies for the 2025 Annual
Meeting. Information regarding the names of such persons and their respective direct or indirect interests in the Company, by